№ files_lp_4_process_3_085869
File format: docx
Character count: 2289
File size: 401 KB
Technical documentation detailing the BINLIST data adapter for verifying credit/debit card information and instructions for integrating it into HCL Foundry applications.
Year:
2024
Platform:
HCL Foundry Volt MX Iris
Supported Devices:
Mobile (iOS, Android), Tablets, PWA
Document Type:
Technical Guide
Topic:
BIN Checker and Data Adapter Integration
Author:
HCL Software Documentation Team
Target Audience:
Developers, API Integrators
Adapter Version:
1.0.0
Date Released:
01-MAR-24
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2020
Region / City:
Brussels
Theme:
Human Brain Project, Software Development, Neuroscience
Document Type:
Proposal Template
Organization:
Human Brain Project
Author:
Not specified
Target Audience:
Applicants, interested parties
Period of Validity:
2020-2021
Approval Date:
5 August 2020
Amendment Date:
Not specified
Call Publication Date:
5 August 2020
Pre-proposal Submission Deadline:
16 September 2020
Proposal Submission Deadline:
16 October 2020
Budget:
EUR 450,000
Keywords:
Brain atlas, The Virtual Brain, Knowledge Graph, HIP, software adapter
Contact Information:
[email protected]
Methodology:
Detailed methodology for proposal activities is outlined
Proposal Length:
Maximum 18 pages, with additional pages per partner
Proposal Submission Platform:
HBP Open Call Platform
Author:
Joe Hatcher
Date:
May 8, 2018
Organization:
SAS
Product:
SAS IT Resource Management 3.8
Related Systems:
VMware vCenter Server, VMware vCenter Server Appliance (vCSA)
Database:
vPostgres (VMware embedded PostgreSQL)
Subject:
Accessing the VMware vCenter vPostgres database via the IT Resource Management Adapter
Security Consideration:
TLS 1.0 vulnerability when accessing vPostgres outside the VMware firewall
Tested Versions:
VMware 6.0, VMware 6.5, VCSA 5.5
Intended Audience:
SAS IT Resource Management customers and support personnel
Document Type:
Internal technical note
Product:
OpenLM ServiceNow Adapter
Related Systems:
OpenLM Server; ServiceNow
Version Requirement:
OpenLM Server v4.6
Database Requirement:
MySQL 5.7 or 8; MSSQL 2012 and up
License Requirement:
OpenLM Server license with External_Platforms support
Installer File:
OpenLM_ServiceNow_Adapter_Installer_#.#.###.msi
Default OpenLM Server Port:
7014
Default External Platforms Service Port:
5005
Configuration Interface:
OpenLM External Platform Configuration
Administration Interface:
OpenLM EasyAdmin User Interface
Integration Scope:
Synchronization of OpenLM data with ServiceNow
Synchronization Options:
Period; Start date; All available data
Notification Options:
EasyAdmin alerts; Email notifications
Authentication:
OpenLM Server credentials; ServiceNow account credentials
Purpose:
Establishing and testing connection between OpenLM Server and ServiceNow
Year:
2026
Product Type:
Serial Adapter
Interface:
M.2 B+M KEY, PCIe 2.0 Gen1
Serial Ports:
4 RS-232
Supported Systems:
Linux kernel 2.6.x/3.x/4.x, Windows XP/Vista/7/8/8.1/10 32/64-bit
Features:
Hardware/software flow control, custom baud rates, remote wakeup, power management, Slow IrDA mode
Package Contents:
Adapter, User Manual, CD, high profile brackets, low profile brackets, 4 DB9-9Pin serial cables
Installation Requirements:
One available M.2 M Key slot, administrative rights for driver installation
Driver Installation:
Windows and Linux supported, specific drivers provided on included CD
Usage:
Provides quad serial connectivity via M.2 interface for desktop systems
Year:
Not specified
Region / City:
Not specified
Topic:
Microwave communication, Radar systems, Test and measurement
Document type:
Product datasheet
Organization / Institution:
YERSON
Author:
Not specified
Target audience:
Engineers, technicians
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2025
Region / City:
[insert local health board name]
Topic:
Community Pharmacy, Common Ailments Service, Docusate Sodium
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
Welsh Medicines Advice Service
Author:
Dianne Burnett
Target Audience:
Pharmacists working within the Common Ailments Service of the Clinical Community Pharmacy Service
Period of Validity:
01 November 2025 - 31 October 2028
Approval Date:
29 August 2025
Review Date:
31 July 2028
Expiration Date:
31 October 2028
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2025
Region / city:
Australia
Subject:
Vocational Education and Training, Health Industry Training
Document type:
Implementation Guide
Organization:
HumanAbility
Author:
HumanAbility, Commonwealth Government through the Department of Employment and Workplace Relations
Target audience:
Registered Training Organisations (RTOs), trainers, assessors, and stakeholders in the VET sector
Period of validity:
September 2025
Approval date:
September 2025
Modification date:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Immunization, Respiratory Syncytial Virus (RSV), Vaccines
Document Type:
Submission
Organization:
SANOFI-AVENTIS AUSTRALIA PTY LTD
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers, immunization program administrators
Period of validity:
From 2024
Approval Date:
24 November 2023
Date of Changes:
17 January 2025
Date of Submission:
7 March 2024
Note:
Contextual Description
Year:
2024
Region / City:
Victoria
Theme:
Agriculture, Horticulture, Conservation, Land Management
Document Type:
Official Guide
Institution:
Department of Jobs, Skills, Industry and Regions (DJSIR)
Author:
Department of Jobs, Skills, Industry and Regions
Target Audience:
Registered Training Organisations (RTOs)
Period of Validity:
From June 2024
Approval Date:
17 June 2024
Changes Date:
N/A
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Year:
2023
Region / city:
Australia
Theme:
Oncology, Chronic Lymphocytic Leukaemia
Document Type:
Resubmission Report
Organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, healthcare policymakers
Period of validity:
Not specified
Approval Date:
November 2019
Date of Changes:
December 2022
Year:
2018
Region / City:
Not specified
Topic:
Performance Qualification for Sequencing System
Document Type:
Protocol
Organization / Institution:
Illumina, Inc.
Author:
Illumina, Inc.
Target Audience:
Illumina certified personnel
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2020
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme (PBS) listing
Document Type:
Committee Submission
Agency:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Committee Secretariat
Target Audience:
Healthcare professionals, PBAC members
Period of Effect:
From May 13, 2020
Approval Date:
May 13, 2020
Modification Date:
Not specified
Year:
2022
Region / City:
Electronic Meeting
Topic:
NR-U bands n46 and n96 – 100 MHz channel BW
Document type:
Meeting Document
Author:
Qualcomm
Target Audience:
RAN4 WG
Period of validity:
February 21 – March 3, 2022
Approval Date:
Not specified
Date of modifications:
Not specified
Description:
A document detailing the discussion and proposals regarding the inclusion of 100 MHz channel bandwidth in NR-U bands n46 and n96, focusing on the coexistence with other technologies and possible configurations.
Note:
Year
Context description:
A procedural manual outlining the registration, suspension, and de-registration criteria for supply customers and their contractual arrangements within the WESM.
Year:
2023
Region / City:
Australia
Theme:
Oncology, Pharmaceutical
Document Type:
Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, policymakers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
USA
Topic:
Computer Science, Programming Languages
Document Type:
Assignment
Institution:
University of Illinois Springfield
Author:
Unknown
Target Audience:
Students of CSC 388
Period of Validity:
Until submission deadline
Approval Date:
2026
Modification Date:
N/A
Year:
2023
Region / City:
Australia
Subject:
Oncology / Colorectal Cancer Treatment
Document Type:
Medical submission
Agency / Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Medical practitioners
Effective Period:
Ongoing
Approval Date:
Not provided
Date of Revision:
Not provided